Stage 3 squamous cell lung cancer: major response to chemo-immunotherapy

Patient Info: Anonymized, Male, 70+ | Stage III

Biomarkers: PD-L1 30-40%

After neoadjuvant chemoimmunotherapy and sleeve right lower lobectomy, pathology showed major pathological response with negative margins, and no metastasis or recurrence was observed 6 months after surgery.

PubMed CentralRead more →

Lung Adenocarcinoma That Transformed to Small Cell Cancer After Recurrence

Patient Info: Anonymized, male, 60s | Stage IV

Biomarkers: PD-L1 1%-24%; no druggable driver alteration identified

Metastatic Site: brain, liver

After treatment for the small-cell-transformed recurrence, the liver metastases showed sustained regression and progression-free survival had reached 13 months by September 2024.

PubMed CentralRead more →

Localized low-grade bronchial chondrosarcoma: surgery with no recurrence at 12 months

Patient Info: Anonymized, Male, 50s

Biomarkers: No molecular biomarkers reported. Histology showed a low-grade cartilage-type tumor.

As of December 2025, follow-up bronchoscopy, CT, and clinical evaluation through 12 months after surgery showed good healing and no recurrence.

PubMed CentralRead more →

Stage IIIA squamous lung cancer: surgery after nivolumab-related complications

Patient Info: Anonymized, Female, 70+ | Stage II

Biomarkers: PD-L1 TPS 99% before treatment; PD-L1 TPS 70% in postoperative hilar lymph node; TPOAb and TgAb normal during thyroiditis workup

As of January 2025, the patient had no recurrence 7 months after neoadjuvant nivolumab/carboplatin/paclitaxel and 5 months after thoracoscopic right upper lobectomy with lymph node dissection.

PubMed CentralRead more →

Lung Adenosquamous Carcinoma Arising From a Long-Standing Bronchogenic Cyst

Patient Info: Anonymized, female, 70+

Biomarkers: KRAS G12D mutation; PD-L1 TPS 60%; EGFR/BRAF/ROS1/ALK negative

She remained in remission 2.4 years after surgery despite stopping atezolizumab early because of immune-mediated colitis.

PubMed CentralRead more →

Stage I lung adenocarcinoma: no recurrence after thoracoscopic lobectomy

Patient Info: Anonymized, Male, 60s | Stage I

No recurrence at 3 months after thoracoscopic right upper lobectomy for pT1cN0M0 lung adenocarcinoma; no additional treatment was needed.

PubMed CentralRead more →

Rare Bronchial Artery Pseudoaneurysm After Lung Cancer Surgery

Patient Info: Anonymized, male

A man in his early 50s underwent right upper-lobe surgery for invasive lung adenocarcinoma and later developed recurrent major bleeding from a rare bronchial artery pseudoaneurysm that was successfully embolized.

PubMed CentralRead more →

Stage 4 lung cancer: complete response to chemoimmunotherapy and surgery

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: EGFR exon 20 duplication with PD-L1 TPS 70%; P40/CK5/6 positive squamous markers; Ki-67 60%.

Metastatic Site: right adrenal gland; possible adjacent…

As of May 7, 2024, CT follow-up showed no evidence of disease after chemoimmunotherapy, conversion surgery with pathologic complete response, and pembrolizumab maintenance.

PubMed CentralRead more →

Right lung cancer with incidental benign cardiac tumor before surgery

Patient Info: Anonymized, Female, 70+

No recurrence was detected at 6 months after staged right upper lobectomy and minimally invasive resection of a benign right atrial papillary fibroelastoma.

PubMed CentralRead more →

ROS1-Positive Stage III Lung Adenocarcinoma With Pathologic Complete Response

Patient Info: Anonymized, male, 40s | Stage III

Biomarkers: ROS1 fusion-positive

Surgery found no residual cancer cells or involved lymph nodes, and no recurrence was detected during 10 months of crizotinib treatment and follow-up.

PubMed CentralRead more →

Stage III Large Cell Lung Cancer With Complete Response to Pembrolizumab-Based Treatment

Patient Info: Anonymized, male, 50s | Stage III

Biomarkers: PD-L1 TPS >60%; no actionable gene mutations identified

Imaging showed complete response of the recurrent hilar and mediastinal lymph nodes, and he remained progression-free through 24 cycles of treatment.

PubMed CentralRead more →

Stage 3 squamous lung cancer: pathological complete response after immunotherapy and surgery

Patient Info: Anonymized, Male, 50s | Stage III

Pathologic complete response after DEB-BACE plus tislelizumab followed by thoracoscopic right middle/lower lobectomy and lymph-node dissection; postoperative chemo-immunotherapy continued and reexaminations were stable.

PubMed CentralRead more →

SMARCA4-deficient lung cancer: no evidence of disease after lobectomy

Patient Info: Anonymized, Female, 60s

Biomarkers: ER, and PR negative.

Alive with no evidence of disease after right lower-lobe lobectomy for SMARCA4-deficient NSCLC, with follow-up imaging negative for recurrence and no significant postoperative respiratory issues or complications reported.

PubMed CentralRead more →

ROS1-Positive Stage III Pulmonary Sarcomatoid Carcinoma With Complete Pathologic Response

Patient Info: Anonymized, male, 60s | Stage III

Biomarkers: ROS1 rearrangement; TP53 mutation; PD-L1 TPS 0%

No recurrence was seen for more than 30 months after surgery following a complete pathologic response.

PubMed CentralRead more →

Stage III Pulmonary Sarcomatoid Carcinoma With Major Response to Neoadjuvant Treatment

Patient Info: Anonymized, male, 50s | Stage III

Biomarkers: PIK3CA mutation; TP53 mutation; PD-L1 TPS 5%

No recurrence was detected for more than 29 months after surgery.

PubMed CentralRead more →

Stage III Pulmonary Sarcomatoid Carcinoma With Major Response and No Recurrence

Patient Info: Anonymized, male, 50s | Stage III

Biomarkers: NRAS mutation; TP53 mutation; PD-L1 TPS 60%

No recurrence was detected for more than 27 months after surgery.

PubMed CentralRead more →

Stage III Pulmonary Sarcomatoid Carcinoma Treated With Neoadjuvant Immunochemotherapy and Surgery

Patient Info: Anonymized, male, 60s | Stage III

Biomarkers: TP53 mutation; PD-L1 TPS 40%

No recurrence was detected for more than 30 months after surgery.

PubMed CentralRead more →

Stage I lung adenocarcinoma: post-lobectomy hemothorax resolved with tPA/DNase

Patient Info: Anonymized, Female, 70+ | Stage I

Early-stage lung adenocarcinoma was surgically treated with left upper lobectomy; postoperative hemothorax resolved after chest-tube drainage, bronchoscopy, and intrapleural tPA/DNase, with no hemothorax recurrence at follow-up.

PubMed CentralRead more →

Stage III lung adenocarcinoma: neoadjuvant brigatinib, surgery, no evidence of disease

Patient Info: Anonymized, Female, 50s | Stage III

Biomarkers: Specific molecular alteration not stated in case 1 raw text; treated with brigatinib

No evidence of disease on PET-CT and brain MRI 27 months after surgery while receiving adjuvant brigatinib 90 mg daily.

PubMed CentralRead more →

Stage III EML4-ALK lung adenocarcinoma: brigatinib, surgery, no evidence of disease

Patient Info: Anonymized, Female, 40s | Stage III

Biomarkers: EML4-ALK fusion rearrangement

No evidence of disease on PET-CT, with no brain metastases on MRI, after 32 months of adjuvant brigatinib following response and surgery.

PubMed CentralRead more →

Stage III EGFR-mutated lung adenocarcinoma: osimertinib and surgery

Patient Info: Anonymized, Female, 70+ | Stage III

Biomarkers: EGFR L858R; EGFR L861Q

No evidence of disease on PET-CT or brain MRI after 42 months of follow-up following neoadjuvant osimertinib and surgery.

PubMed CentralRead more →

Stage 1 lung cancer found after chest injury

Patient Info: Anonymized, Female, 70+

No lung cancer recurrence and no cardiovascular events were reported 12 months after right lower lobectomy and lymph node dissection for Stage IA2 papillary lung adenocarcinoma.

PubMed CentralRead more →

Stage III MET Exon 14-Positive Lung Adenocarcinoma Treated With Targeted Therapy Before Surgery

Patient Info: Anonymized, male, 60s | Stage I

Biomarkers: MET exon 14 skipping mutation; TP53 mutation

Postoperative pathology showed no involved lymph nodes and a lower pathologic Stage I group after treatment. No relapse was seen at the 6-month postoperative follow-up.

PubMed CentralRead more →

Recurrent Lung Adenocarcinoma Complicated by a Tracheopericardial Fistula

Patient Info: Anonymized, male, 70+ | Stage II

Biomarkers: No gene mutations identified on postoperative testing

He died during the June 2024 admission, about 7½ years after his November 2016 lung-cancer diagnosis, after massive hemoptysis occurred in the setting of a tracheopericardial fistula and recurrent cancer.

PubMed CentralRead more →